A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

(2018) Tiziano Barbui et al.   Blood Cancer Journal

Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia

(2017) Fabrice Usseglio et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders–A consensus project of the Italian Society of Hematology

(2017) Paola Guglielmelli et al.   LEUKEMIA RESEARCH

Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR

(2016) Miguel Waterhouse et al.   ANNALS OF HEMATOLOGY

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

(2016) G Barosi et al.   LEUKEMIA

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

(2014) A. Tefferi et al.   BLOOD

Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis

(2014) E. Lippert et al.   HAEMATOLOGICA

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

(2014) A Tefferi et al.   LEUKEMIA

Myelofibrotic Transformations of Polycythemia Vera and Essential Thrombocythemia are Morphologically, Biologically, and Prognostically Indistinguishable From Primary Myelofibrosis

(2014) Nikhil Sangle et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

CLINICAL IMPLICATIONS OF JAK2 MUTATIONS IN MYELOPROLIFERATIVE DISORDERS

(2014) L. Knoops et al.   ACTA CLINICA BELGICA

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse

(2013) T. Lange et al.   HAEMATOLOGICA

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

(2013) J V Jovanovic et al.   LEUKEMIA

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection ofJAK2V617F and other relevant mutations

(2012) Anthony J. Bench et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mutational Status of Myeloproliferative Neoplasms

(2012) Elisa Rumi et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

JAK2V617F allele burden is associated with transformation to myelofibrosis

(2012) Maya Koren-Michowitz et al.   LEUKEMIA & LYMPHOMA

Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms

(2011) N. C. P. Cross   Hematology-American Society of Hematology Education Program

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

(2010) A Tefferi   LEUKEMIA

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

(2009) P. Guglielmelli et al.   BLOOD

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

(2009) N. Kroger et al.   BLOOD

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones

(2009) Philip A. Beer et al.   BRITISH JOURNAL OF HAEMATOLOGY

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

(2009) S. A. Bustin et al.   CLINICAL CHEMISTRY

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

(2008) E. Antonioli et al.   HAEMATOLOGICA

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

(2008) A M Vannucchi et al.   LEUKEMIA